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1. Introduction
Sex hormones are implicated in immune response, with estrogens acting as enhancers [10].
Estrogens not only have anti-inflammatory but also pro-inflammatory roles depending
upon different influencing factors [66]. Metabolism of estrogen within the body is a complex
and important subject. Estrone and estradiol are biochemically interconvertable and yield
the same family of estrogen metabolites. The metabolism of estrogen takes place primarily
in the liver through Phase I (hydroxylation) and Phase II (methylation, glucuronidation, and
sulfation) pathways with ultimate excretion in the urine and feces [26].
Cytochrome P-450 enzymes mediate the hydroxylation of estradiol and estrone, which is the
major Phase I metabolic pathway for endogenous estrogens. Several extrahepatic target tis‐
sues or cultured cells from target tissue express estrogen-hydroxylating enzymes activities
[28]. Each cytochrome P-450 favors the hydroxylation of specific carbons, altogether, these
enzymes can hydroxylate virtually all carbons in the molecule, with the exception of the in‐
accessible carbons. Different functional groups produced by the action of P-450 at the specif‐
ic sites of steroid nucleus markedly effects the biological properties of different estrogen
metabolites. For example, different hydroxylation reaction give estrogenic or carcinogenic
metabolites. Functionally, the important reactions catalyzed by cytochrome P-450 are at car‐
bon number 2, 4 and 16.
In this chapter, we venture into the area of the ambiguous relationship between catecholes‐
trogens (CEs) and rheumatoid arthritis (RA). This analysis is focused in a part on the possi‐
ble role of CEs in the pathogenesis of RA and on exploring the mechanism behind the
generation of autoantibodies taken consideration the role of CEs. It also explains a unique
hypothesis, which showed that CEs formed in various tissues undergo oxidative metabo‐
lism (enzymatic or non-enzymatic) to produce reactive oxygen species (ROS), which could
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modified DNA and alter it immunogenicity. This would lead to the induction and elevated
levels of RA autoantibodies. In addition, chapter further explain the role of CEs in antigen-
driven induction of RA autoantibodies that may unfold various aspects of RA.
2. Catecholestrogens (CEs)
Catecholestrogens (CEs) are biological active metabolites of estrogen which are synthesized
by estrogen 2- and 4- hydroxylase in the liver, brain and other organ [29]. They are pro‐
duced by the actions of genes encoded by CYP1A1, CYP1A2 and CYP1B1, which is an estro‐
gen 4-hydroxylase (Figure 1).
Figure 1. Pathway of estrogen metabolism including estradiol, estrone and various estrogen metabolites (including CEs).
CEs also yield potent genotoxic molecules implicated in carcinogenesis. 4-Hydroxyestrone/
estradiol was found to be carcinogenic in the male Syrian golden hamster kidney tumor
model,  whereas  2-hydroxylated  metabolites  were  without  activity  [46].  4-Hydroxyestro‐
gen can be oxidized to quinone intermediates that react with purine base of DNA, result‐
ing  in  depurinating  adduct  that  generates  highly  mutagenic  apurinic  sites.  Quinones
derived from 2-hydroxyestrogens produced stable DNA adducts and are presumed to be
less  genotoxic  [67].  As  described elsewhere,  estrogen may be  oxidized by  hepatic  cyto‐
chrome  P-450  enzymes  to  hydroxyl  CEs  and  further  oxidized  to  the  semiquinone  and
quinone form [1]. The quinone formed from oxidation of 4-hydroxyestrogen has half-life
of 12 minutes as compared with the short life of 2-hydroxyestrogen (t1/2  = 47 s) [30].  Es‐
trone  and estradiol  are  oxidized to  lesser  amount  to  2-hydroxycatechols  by  CYP3A4 in
liver and by CYP1A in extrahepatic tissues or to 4-hydroxycatechols by CYP1B1 in extra‐
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hepatic sites, with the 2-hydroxycatechol being formed to a larger extent. Catechol-o-meth‐
yl transferases (COMTs) inactivated 2- and 4-hydroxycatechols to their respective methyl
derivatives [69].  COMT, a phase II  enzyme, catalyses the transfer of methyl group from
S-adenosyl methionine to hydroxyl groups of a number of catechol substrates, including
the catecholestrogens.  CEs under  normal  condition are  o-methylated by COMT to  form
2- and 4-o-methylethers, which are excreted in the urine [56]. Small amount of CEs may
also be converted by peroxidase-catalysed reactions to semiquinones or quinones that are
capable  of  forming  DNA  adducts  or  generating  ROS  via  redox  cycling  that  could  oxi‐
dize DNA bases [69]. Estrogen metabolites have indirect and direct genotoxicity. Hydrox‐
ylation is an important elimination step for estrogen to generate CEs. Microsomal estradiol
hydroxylation in human breast cancer showed significantly higher 4-hydroxy:2-hydroxyes‐
tradiol  ratio  in  tumor  tissue  than  in  adjacent  normal  breast  tissue  [48],  but  the  breast
cancer tissue samples contained fourfold higher levels of 4-hydroxyestradiol (4-OHE2) than
in normal tissue from benign breast biopsies [57].
It has been observed that intra-tissue concentration of estrogens, hydroxyestrogens (16 α-hy‐
droxyestrone, 2-hydroxyestrone, 2-hydroxyestradiol, 4-hydroxyestrone, and 4-hydroxyes‐
tradiol) and methoxyestrogens (2-methoxyestrone, 2-methoxyestradiol, 4-methoxyestrone,
and 4-methoxyestradiol) in normal and malignant breast showed the highest concentration
of 4-hydroxyestradiol in malignant tissue [4]. The concentration, as evaluated by combined
high performance liquid chromatograpy (HPLC) and gas chromatograpy-mass spectrome‐
try (GC-MS) was found to be more than twice as high as that of any other compound. CEs
have been measured in rat brain and various endocrine tissues by sensitive radioenzymatic
assay. The concentration of these CEs in the hypothalamus and pituitary are at least ten
times higher than parent estrogen. CEs have potent endocrine effect i.e. they have an impor‐
tant role in neuroendocrine regulation [54].
In addition, brain is capable of 2-hydroxylation and consequently forms CEs from estrone
and estradiol. Increased availability of estrogen and estradiol for binding and hypothalamic
sites would facilitate formation of CEs. 2-Hydroxylated and 4-hydroxylated estrogen exerts
biologic responses on the cyclic secretion of leutenising hormone (LH) perhaps even on folli‐
cle stimulating hormone (FSH) and prolactin. Catecholestradiol competes with estradiol for
estrogen binding sites in the anterior pituitary gland and hypothalamus and dopamine
binding sites on anterior pituitary membranes [41].
Mitogenicity associated with estrogen receptor (ER)-mediated cellular events was believed
to be the mechanism by which estrogens contributed to carcinogenesis [59]. The role of CEs
as genotoxic chemical procarcinogenesis, independent of ER mediation, has been well recog‐
nized [70]. Although oxidative metabolism of estrogen to CEs is generally thought to termi‐
nate the estrogenic signal, but CEs retain some binding affinity to the ER. Exposure of
MCF-7 cells with 2- and 4-hydroxyestradiol increased the rate of cell proliferation and the
expression of estrogen-inducible gene such as progesterone receptor (PR) gene and pS2.
Compare to estradiol, 2- and 4-hydroxyestradiol increased proliferation rate, level of PR pro‐
tein as well as pS2 mRNA expression to certain fold [62].
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As describe previously, estrogens are metabolized via two pathways i.e. formation of CEs
and to lesser extent, 16 α-hydroxylation. The catechols are formed as 2- and 4-hydroxylated
estrogen. These two CEs can be inactivated by the enzyme COMT through o-methylation
[69]. Other possible mechanism of inactivation includes conjugation of CEs by glucouroni‐
dation and sulphation. High concentration of 4-hydroxylated metabolites caused insufficient
production of methyl, glucouronide or sulphate conjugate which in turn results in CE toxici‐
ty in cell and consequently competitive catalytic oxidation to semiquinone (CE-SQ) and qui‐
none (CE-Q). CE-SQ and CE-Q may conjugate with glutathione (GSH), catalyse by S-
transferase. CE-Q may also react with DNA to form stable and de-purinating adduct if this
inactivating process is incomplete [47].
3. CEs and DNA
Endogenous estrogens can become carcinogenic via formation of catecholestrogen quinones,
which react with DNA to form specific estrogen-DNA adducts. The mutations resulting
from these adducts can cause cell transformation and initiation of breast cancer [58]. The 4-
hydroxyestrogen generates free radicals from reductive-oxidative cycling with the corre‐
sponding CE-SQ/CE-Q forms, thus causing DNA damage extensively. In comparison to 4-
hydroxyestrogen, 2-hydroxyestrogen is not carcinogenic and has potent inhibitory effect on
the growth of tumor cells and on angiogenesis [17]. The DNA adducts generated by 2-hy‐
droxyestrogen and 4-hydroxyestrogen can form stable modifications that remain in the
DNA unless they are removed by repair. On the other hand, the modification bases can be
released from DNA by destabilization of the glycosydic bond and result in the formation of
depurinated or depyrimidinated sites [7].
Earlier studies from our lab showed that CE modified DNA brings about single and dou‐
ble  strand  breaks,  hyperchromicity,  damage  at  the  restriction  sites  and  modification  of
different bases (Table 1) [40, 36, 37, 38]. It has been observed that CE caused more dam‐
age to the DNA in presence of copper in comparison to nitric oxide (NO) as the extent of
base modification was greatest for thymine followed by guanine, adenine and cytosine [40].
We proposed that  CE and NO formed in  different  tissue  may react  with  each other  to
produce CE-Q.
The quinone/semiquinone redox system produces superoxide ions (O2¯ ) which can react
with NO to form peroxynitrite, which could cause DNA damage [38]. Quenching studies of
DNA modified with CEs in presence of C(II) showed that catalase and bathocuproine
strongly (~ 80 %) inhibited the modification by CEs plus Cu(II) indicating the involvement
of H2O2 and Cu(I) during the modification [36, 37]. These results demonstrate that CEs lead
to the production of potent ROS, capable of causing DNA damage, thus playing important
role not only in carcinogenesis [36] but also in systemic lupus erythematosus (SLE) [40, 37,
39] and RA [38].
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Parameter Native DNA CE-modified DNA
Hyperchromicity — 32.2
Absorbance ratio (A260/A280) 1.86 1.52
Melting temperature (Tm) ºC 88 80.5
S1 nuclease action No digestion Digestion
Restriction enzymes
PvuI (CGAT↓CG) Digestion No digestion
PvuII (CAG↓CTG) Digestion No digestion
SspI (AAT↓ATT) Digestion Digestion
Circular dichroism (mdeg) Wavelength (nm)
+274 0.77 0.52
−246 −1.3 −7.60
−210 −0.85 −0.58
Scavengers inhibition of modification
Catalase — 82
Sodium azide — 21
Bathocuproine — 80
Ascorbic acid — 35
Base modification
Adenine — 16.9%
Guanine — 45.5%
Cytosine — 12.6%
Thymine — 47.1%
Table 1. Characterization of Native and CE-modified DNA under identical experimental conditions. (Adapted from
[36]).
Over the last 2 decades, only two studies have been reported that explain the presence of CE
adducts in human breast tissue. First study involves the analysis of CE adducts in the DNA
from malignant breast tumor. DNA sample showed the presence of deoxyguanosine ad‐
ducts of 4-hydroxyestradiol and 4-hydroxyestrone in almost every samples [21]. Other study
showed the presence of CE quinone-derived DNA adduct in two breast samples that were
collected from one women with and one woman without breast cancer [51]. The catechol
quinone-derived adducts identified were 4-hydroxyestradiol-1-N3-adenosine, 4-hydroxyes‐
trone-1-N3-adenosine and 4-hydroxyestradiol-1-N7-guanine. Animal experimentation in‐
volves the injection of 4-hydroxyestradiol (or estradiol-3,4-quinone) into the mammary
glands of female ACI rats which resulted in the formation of the depurinating adducts, 4-
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hydroxyestradiol-1-N3-adenosine and 4-hydroxyestradiol-1-N7-guanine. [47]. In addition to
these adducts, 4-hydroxyestradiol-GSH conjugates was also detected. Another study dem‐
onstrates the presence of 4-hydroxy catecholestrogen conjugates with GSH or its hydrolytic
product (cysteine and N-acetylcysteine) both in tumors and hyperplastic mammary tissues
in ERKO/Wnt-1 mice [18]. Estradiol-3,4-quinone reacted rapidly to form 4-hydroxyestra‐
diol-1-N3-adenosine adducts that are considered to be as depurinating adducts.
It has been shown that CEs can induce DNA lesions not only in plasmid DNA [40, 36, 37, 38]
but also in calf thymus DNA [49]. In short, quinone intermediates produced by oxidation of
the CE 4-hydroxyestradiol or 4-hydroxyestrone may react with purine bases of DNA to form
depurinating adducts that generate highly mutagenic apurinic sites. In contrast, quinone of
2-hydroxylated estrogen produce less harmful and stable DNA adducts [7]. The CE metabo‐
lites may also produced potentially mutagenic oxygen radicals by metabolic redox cycling
that can also caused DNA damage. The abasic sites resulting from the spontaneous depuri‐
nation-depyrimidination of the modified bases and the aldehydic base and sugar lesions re‐
sulting from the oxidative damage to deoxyribose moieties in the DNA molecules [49],
disturb the structural integrity of DNA and destabilize the double helix. This would alter it
property and render DNA immunogenic.
4. CEs and Immune Response
Despite a large number of reports that may explain the role of estrogen (or estradiol) in
modulation of immune response [10, 66], the role of CEs in the immune response is lacking.
It has been observed that the conversion from 2-hydroxysetrogens to 4-hydroxyestrogen
might be an additional pro-inflammatory signal because these endogenous metabolites can
be oxidized to 3,4-quinone, which lead to depurination and mutation [49]. The 3,4-semiqui‐
none and quinone produce ROS, which stimulate inflammation, whereas methylation and
sulfation are detoxification pathways, which involve the release of detoxying agents in the
urine [56]. Other pro-inflammatory role of 4- hydroxyestrogen can be explain by the fact that
4-hydroxyestradiol undergoes 2-electron oxidation to quinone via semiquinone and during
this process, ROS can be generated to cause DNA damage and cell death [8]. A similar effect
was observed in our studies that explained extensive DNA damage and base modification
[40, 36, 37, 38, 39]. In contrast to the pro-oxidant activities of 4-hydroxyestradiol, 2-hydrox‐
yestradiol is a antioxidant that show no carcinogenic activities and has potent inhibitory ef‐
fect on the growth of tumor cells and on angiogenesis [17]. Thus, 4-hydroxyestradiol in
comparison to 2-hydroxyestradiol induce carcinogenesis and have pro-inflammatory effects
[20]. But now, we are unaware of the fact that whether pro-inflammatory mediators induce
a shift from 2-hydroxyestrogen to 4- and 16-hydroxylated estrogens. From all these studies
there is a clear evidence that 2-methoxyestradiol is a pro-apoptotic and cytostatic endoge‐
nous compound, which can inhibit not only angiogenesis [17] but also inflammation in ani‐
mal models. In contrast, 4-hydroxylated estrogens might exert pro-inflammatory roles by
inducing ROS and DNA damage. Just like conversion from 2-hydroxyestrogens to 4-hydrox‐
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yestrogens, a shift to 16 α-hydroxylated forms of estrogen can be an important pro-inflam‐
matory and pro-proliferative signal [66].
The direct role of CEs in mediating immune response can be explain in our studies that
demonstrate the production of antibodies to CE-modified plasmid DNA [40, 36, 37, 39, 38].
As reported earlier, CE-modified DNA (CE-DNA) was found to be highly immunogenic (>
1:12800) in animal model [36]. These antibodies were effectively used as probe for detecting
oxidative lesions in human genomic DNA as well as for the estimation of 8-hydroxy-2’-de‐
oxyguanosine (8-OHG) level in the urine of cancer patients [36] and RA patients [38]. Anti‐
bodies evaluated from competition ELISA showed strong specificity for the CE-DNA
(immunogen) causing about 92 % inhibition in anibody binding at 20 μg/ml of the immuno‐
gen (competitor) concentration. Fifty percent inhibition was observed at 3.5 μg/ml of the im‐
munogen. In addition, these antibodies showed a very high degree of binding toward 8-
OHG that may explain the role of ROS in mediating various immune responses including
inflammation. CE-modified form of different bases (adenine, guanine, cytosine, thymine),
human and calf thymus DNA, ROS-DNA, poly nucleotides (dT, dA, dC, dG, dA-dT) were
also recognized by these antibodies. Another evidence that explain the role of CEs in media‐
ting immune responses comes from our previous study that showed that CE-DNA was not
only recognized highly by cancer autoantibodies [36] but also by anti-DNA autoantibodies
in SLE [40, 37] and RA [38]. Results from all these studies demonstrate that CEs somehow
produce some antigenic stimulus that may contribute to the generation of antibodies which
may directly or indirectly affect the immune system.
Dual pro-inflammatory and anti-inflammatory role of estrogens has been described earlier
[66], which depend on the immune stimulus, subsequent antigen-specific immune response,
the cell types involved during different disease phase, the specific microenvironment, tim‐
ing of estrogen administration in relation to the disease course, the concentration of estro‐
gen, the variability in expression of estrogen receptor depending on the microenvironment
and the cell type and intracellular metabolism of estrogen leading to important biologically
active metabolites (CEs) with quite different anti- and pro-inflammatory function. In addi‐
tion, one of the striking property of estrogen is its ability to differentiate T and B cells, in‐
crease immunoglobulin production and increase immune complex-mediated disease such as
SLE [9]. It has been found that women, who are diagnosed with breast cancer, have signifi‐
cantly elevated anti-HMdU autoantibodies [23]. This study is in agreement with our previ‐
ous finding that explains the presence of circulating antibodies against CE-modified DNA in
cancer patients [36]. The modified DNA presents unique epitopes which may be one of the
factors for autoantibody induction in cancer. The presence of high levels of these antibodies
proves to be the pro-oxidant conditions that have led to the oxidation of bases in genomic
DNA and have stimulate an immune response. Since native DNA is a known weak immu‐
nogen, it appear that DNA damage by CE render it immunogenic leading to the induction of
cancer autoantibodies. It has been suggested that the oxidative DNA damage and the immu‐
nologic responses it evokes (autoantibodies) start occurring not only in the carcinogenic
process [36] but also in various autoimmune diseases [40, 36, 37, 39, 38]. Estrogen also mod‐
ulate the function of PMNs (poly morphonuclear leukocytes, neutrophils, granulocytes),
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which in turn cause the production of ROS on their stimulation. ROS generated by PMNs
cause DNA modification as well as oxidation of protein and lipid peroxidation. It is interest‐
ing to note that 2-hydroxylated estrogens works as powerful inhibitors of PMNs activity,
which shows one of the protective property of the 2-hydroxylated CEs. Therefore, estrogens
(and estrogen metabolites like CEs) affect immunological responses and in turn, their activi‐
ties are affected by the immunological products. In addition, estrogen in physiological con‐
centration serves to enhance immune response by inducing the production of various types
of cytokines and interleukins.
5. CEs and Cytokines
The sex hormones are likely to directly modulate the function of cells involved in the im‐
mune response [42]. The pro- and anti-inflammatory effects of estrogen and their metabo‐
lites (CEs) on secretion of pro-inflammatory cytokines have been a matter of debate for two
or three decades. In fact, at physiological dose, estradiol induce IL-1α, a cytokine that can
initiate a cascade of other cytokines, chemotactic and growth factors [12]. It is interesting to
note that estradiol also inhibits IL-1α-induced IL-6 production. Therefore, estradiol not only
results in increased human epithelial cell proliferation (a process important in tumor
growth) but also inhibits the activity of natural killer cells, thus allowing tumor growth [52].
Estrogen and their metabolites (such as CEs) stabilized or increased cytokine secretion
whereas testosterone inhibited this secretion [32]. This study explains that down stream es‐
trogen, 2-hydroxyestradiol (2-OHE2), 4-OHE2 and 16-hydroxyestradiol (16-OHE2) did not
stimulate TNF secretion. However, the combination of 16-OHE2 and 2-OHE2 or 4-OHE2
markedly stimulated TNF secretion that was observed in presence of cortisol. Therefore, at
physiological concentration, estradiol and a combination of downstream estrogens (like 2-
OHE2, 4-OHE2 and 16-OHE2) increased (or stabilized) immune stimuli-induced TNF secre‐
tion. In addition, estradiol also caused the production of IL-6, IL-2, IFNγ, IL-4 and IL-10,
caused by the pro-inflammatory influence of applied immune stimuli [32]. The study of Ja‐
nele et al, 2006.] demonstrates that ratio of 16-hydroxylated estrogen in relation to 2-/4-hy‐
droxylated estrogen is important for TNF secretion. It has been found that the ratio of 10:1 of
16-OHE2 in relation to 2-/4- hydroxylated estrogen markedly stimulated TNF secretion in
presence of cortisol (Figure 2).
In addition, in absence of cortisol, the combination of 16-hydroxylated and 2-hydroxylated
estrogens even strongly inhibited TNF secretion. During chronic inflammatic conditions, ad‐
ministration of therapeutic estrogens increased 16-hydroxylated estrogens. In addition, dur‐
ing chronic inflammation in the situation of rheumatic diseases (example RA) the balance is
switch to estrogen and particularly to 16-hydroxylated estrogen. In conclusion, one should
assume that therapeutic administration of estrogen would enhance 16-OHE2 over 2-/4-hy‐
droxylated estrogens, which would support secretion of pro-inflammatory cytokines.
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Figure 2. Effect of estrogen and their catechol metabolites (CEs) on the secretion of pro-inflammatory cytokines in RA.
It has been observed that estradiol increased IgG and IgM production by peripheral blood
mononuclear cells (PBMC) in patients of SLE. This led to elevated levels of polyclonal IgG
(including IgG anti-dsDNA) by enhancing B-cell activity by way of IL-10 [33]. It should be
important to check these results in the presence of 16 α-hydroxyestrone (16-OHE1) and the
naturally occurring 2-hydroxylated CE. Previous study shown that decrease activity in SLE
patients correlated negatively with urinary concentration of 2-hydroxylated estrogens [68].
Interestingly, estradiol increase IL-10 production by monocytes and exogenous IL-10 further
enhances estradiol-induced increase in antibody production by B cells. Therefore, in SLE pa‐
tients, estradiol increases IL-10 production by patient’s monocytes and exogenous IL-10 acts
additively with estradiol to increase antibody production of B cells. It is hypothesized that
estradiol-estradiol receptor complexes may enhance the transcription of IL-10 genes by
binding to estrogen-responsive elements or by binding to some transcription factor that di‐
rectly bind those elements [24].
High doses of estrogen (1500-2000 pg/ml) administration to non-overiectomized mice ame‐
liorated disease systems and significantly decreased the percentage of TNF α or IFNγ pro‐
ducing CNS antigen-specific T Cells in both the CNS and spleen [31]. However, similar
studies in mice lacking IFNγ, IL-4 and IL-10 genes provide evidence that these cytokines
may not be necessary for estradiol-mediated improvement of disease severity, discrediting
the notion that an estrogen-induced shift towards Th 2 cytokine involved [31]. Estrogen also
stimulates secretion of IL-4, -5, -6 and -10 by TH 2 lymphocytes. These cytokines are potent
stimulators of B-cell proliferation, maturation into plasma cells and synthesis of antibody.
Interleukins 4, 5, 6 and 10 are expressed in greater amount in an estrogen-dominant hormo‐
nal milieu [53]. SLE patients have increased level of IL-6 and IL-10, product of TH2 lympho‐
cytes and macrophages, which can be directly correlated with clinical disease severity [53].
Patients with lupus also have an inherent defect in interferon gamma production. Under
normal condition, increased estrogen leads to an increase interferon gamma concentration
but in SLE patients, the estrogen-associated increase in interferon gamma secretion is absent
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[53]. In addition, interesting changes of serum estrogens that correlated with cytokine varia‐
tion have been found during pregnancy in SLE patients [19]. The local effect of sex hor‐
mones in autoimmune rheumatoid disease (RA) seem to consist mainly of altered cell
proliferation (i.e. estrogen enhance) and cytokine production.
6. Reminding the concept of rheumatoid arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune disease whose aetiology and progression are
multifactorial, including a range of immune, neuroendocrine and psychosocial variable [14].
How these variable interact with one another and how they ultimately influence the disease
process in RA is only partially know. A growing body of evidence showed that the stress
system and its interaction with the immune system, play a vital role in RA [14]. RA is more
prevalent among women than men and 80 % of the total cases occurring between the age of
35 and 50 [34]. The primary presenting symptoms are pain, stiffness and swelling of the joints
resulting in impaired physical function. Synovial inflammation underlines the cardinal man‐
ifestations of this disease, which include pain, swelling and tenderness followed by cartilage
destruction, bone erosion and subsequent joint deformities. In RA, joint involvement is typi‐
cally symmetric, a characteristic usually not found in other forms of arthritis [50]. Early theories
on the pathogenesis of RA focused on autoantibodies and immune complexes, T cell-mediat‐
ed antigen-specific responses, T cell-independent cytokine network and aggressive tumor-
like  behavior  of  synovium have  also  been  implicated  [22].  Recently  the  contribution  of
autoantibodies in RA has come in the front line and specific therapeutic interventions can be
designed to suppress synovial inflammation and join destruction in RA [22].
RFs have been the hallmark autoantibody found in RA [71]. Autoantibodies to the major car‐
tilaginous collagen have been found in the sera of some RA patients. In addition, cross-reac‐
tive natural autoantibodies (IgM) have been described in the sera of RA patients [25]. These
antibodies are predominantly directed against histone moieties or against double-stranded
DNA. Anti-ds DNA has also been reported following treatment of RA with IFNγ. Beside
that, autoantibodies have been found in the sera of RA patients that showed preferentially
high binding of CE-modified DNA [38]. In addition, the antibodies have been shown to rep‐
resent a alternative immunochemical probe to detect oxidative lesions in DNA (genomic) as
well as for the estimation of 8-OHdG level in different body fluid of RA patients [38], which
may be used as marker in the diagnosis of the disease. Many autoantibody system that
could participate in inflammatory joint disease are now recognized in RA, including rheu‐
matoid factor, type II collagen, immunoglobulin heavy gene binding protein, heat shock
proteins and hn RNP-33 [64]. Anti-collagen antibody and rheumatoid factor are produced
by rheumatoid synovial B cells. The ability of ubiquitous antigen (glucose-6-phosphoisomer‐
ase) to induce synovial inflammation is probably related to their adherence to the cartilage
surfaces. The presentation of immobilized antigen-antibody complexes on cartilage provides
an exceptionally good substrate for complement fixation, similar to rheumatoid factor em‐
bedded in rheumatoid cartilage.
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Macrophage-derived cytokines (like tumor necrosis factor alpha, TNF α) know to play an
important role in the induction and perpetuation of the chronic inflammatory processes in
rheumatoid joints as well as in the systemic manifestation of this disease [27]. Over produc‐
tion of this cytokines in the joints of RA patients triggers increase in synoviocyte prolifera‐
tion and a cascade of secondary mediators involved in the recruitment of inflammatory cells
and in the process of joint destruction [3]. It has been found that increase inflammatory
markers are responsible for disease progression and joint destruction in early RA. Infect the
rate of cartilage and joint destruction is correlated with plasma elevation in inflammatory
acute phase reactants (C-reactive protein and vascular endothelial growth factor) and in the
synovial concentration of matrix metalloproteinase, matrix digesting enzymes directly re‐
sponsible for joint damage [2].
In recent years the treatment of RA has undergone somewhat of a revolution, with a strong
consensus emerging in favor of early, aggressive therapy [63]. There is growing evidence
that early treatment of the disease has a beneficial impact on treatment outcome. The goal to
be achieved in managing RA are to explain the underline mechanism behind the generation
of antibodies to cartilaginous collagen as well as other oxidative stress condition generated
in the synovial fluid, which may be used as marker in the early diagnosis of the disease.
7. Role of CEs in the aetiopathogenesis of RA
Estrogen and their CE metabolites know to play an important role in autoimmune rheumat‐
ic diseases [38, 68, 15]. A role for estrogen in the pathogenesis of RA has been review for the
last few years [66, 70, 38, 12, 32, 68, 15] but the exact patho-aetiology remains elusive. The
evidences concerning the possibility of CEs in the development of RA are very limited and
preliminary. It has been observed that the ratio of 16-OHE1/4-OHE2 in synovial fluid (SF) of
RA was found to be significantly higher than control [6]. In addition, SF level of 4-OHE2 was
significantly increased in RA patients compared to controls [5]. Interestingly, urinary con‐
centration of 2-hydroxylated estrogen were 10 times lower in patients with RA than in
healthy individuals but the ratio of 16-OHE1/2-hydroxylated was 20 times in RA patients as
compared to control [68]. These finding suggests that the magnitude of conversion to the mi‐
togenic 16-OHE1 is extremely upregulated in RA which most likely contributes to the main‐
tenance of the disease. Furthermore, peripheral estrogen hydroxylation was found to be
increased in both men and women with SLE and estrogenic metabolites were reported to in‐
crease B cell differentiation and activate T cells [44].
Both RA and SLE are associated with an altered sex hormone balance characterized by lower
amount of immunosuppressive androgens and higher amount of immune enhancing estro‐
gens [15].  Increased estrogen to androgen ratios have been observed in RA patient’s  SF
because of increased aromatase expression by inflammatory macrophages infiltrating syno‐
vial tissue [5]. Increased estrogen concentration in RA SF from patients of both sex likely
results from the pro-inflammatory cytokines TNFα, IL-1β and IL-6,  which accelerate the
metabolic conversion of estrogen from androgen by inducing the synovial tissue aroma‐
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tase (Figure 3). As a result, increased estrogen level might exert activating effects on syno‐
vial cell proliferation including macrophages and fibroblast [35]. Interestingly, renal excretion
studies showed that the enhanced estrogen metabolism observed in both RA and SLE pa‐
tients resulted in elevation of pro-inflammatory metabolites derived from estrone or estra‐
diol such as 16-OHE1, which exert mitogenic effects and may induce proliferation of synovial
fibroblast [68, 13]. In addition, RA SF showed reduced amounts of anti-inflammatory estro‐
gens metabolites such as 2-hydroxyestrogen that inhibits the growth promoting effects of
estrogen. In contrast, 16-OHE1 metabolites considered as enhancer of cell proliferation. In
RA synovial tissue, biological effects of estrogen metabolites as a consequence of altered
peripheral  sex  hormone synthesis  mainly  results  in  stimulation of  cell  proliferation and
cytokine production [11].
Figure 3. Immune modulation by estrogen and their metabolites in the synovial tissue of RA patients.
It has been observed that RA synovial cells mainly produce the cell pro-proliferation 16-
OHE1,  which in addition to 16-OHE2,  is  the downstream estrogen metabolites that inter‐
feres with monocyte proliferation. In addition, urinary concentration and total urinary loss
of 2-hydroxyestrogen was found to be 10 times higher in healthy subjects compared to RA
[11]. Peripheral metabolic conversion of androgens to potent metabolites of estrogen that
promote immune cell proliferation and activation may have role in the female predisposi‐
tion to autoimmunity.
Estrogen represent a risk factor for the development of autoimmunity and therefore, their
therapeutic use must be avoided in patients with active immune-mediated diseases specially
RA [16]. In addition to estrogen, various CE metabolites know to increase the risk for the
development of RA disease. The increased estrogen concentration has been observed in RA
SF, where the hydroxylated forms make the major concentration in particular 16-OHE1 and
4-OHE2 whereas, the 2-OHE1 was found to be similar to the controls [6, 5]. As describe early,
16-OHE1 is a mitogenic and proliferative endogenous hormone which is responsible for the
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proliferation of synovial fibroblast [13]. 16-OHE1 is formed from upstream estrone and estra‐
diol, which show biological responses by covalent linkage to the receptor [61]. The other
conversion product of estrone and estradiol are the 2-hydroxylated estrogens such as 2-
OHE2 and 2-OHE1, which would classified as CE. In comparison to 16 hydroxylated estro‐
gens, the 2-hydroxylated forms of estrogen inhibit growth-promoting effects of estradiol
[61]. In one of the previous study, it has been observed that urinary levels of 2-hydroxylated
estrogens were found 10 times lower in RA patients in comparison to normal subjects,
whereas the ratio 16-OHE1/2-hydroxyestrogens was found to be 20 times higher in RA pa‐
tients than in healthy controls [68]. Decreased loss of 2-hydroxylated estrogen in relation to
the mitogenic 16-OHE1 might provide important stimulus to support proliferative state of
the synovial cells in RA. Therefore, concentrated-related conversion to pro- and anti-inflam‐
matory down stream metabolites of estrogen might support dual role of estrogen (pro- or
anti-inflammatory) [13].
Estrogen at physiological concentration serves to enhance immune responses that may act as
important driving force for human humoral immunity [65]. Estradiol increase IL-10 produc‐
tion by monocytes and exogenous IL-10 further enhance estradiol-induced increase in anti‐
body production by B cells. In addition, estradiol enhances IgG and IgM production by
PBMC, which leads to elevated levels of polyclonal IgG, including IgG anti-DNA in PBMC
of SLE patients by enhancing B cell activity via interleukin 10 [33]. These studies are in
agreement with our previous studies that describe the role of CEs in the etiopathogenesis of
SLE, cancer and RA [40, 36, 37, 38, 39]. To have a better insight into the possible role of CEs
in the aetiopathogenesis of RA, we have demonstrated that CE-modified DNA was highly
recognized not only by SLE IgG [40, 37, 39] and cancer IgG [36] but also by RA IgG [38],
pointing out the possible participation of modified DNA in the pathogenesis of various au‐
toimmune diseases including RA, as it has been reported that CE-modified DNA bases
cause DNA strand breakage and adduct formation in vivo and in vitro [7]. CE-modified
DNA showed preferentially high binding with RA sera when compare with nDNA (p <
0.001). These studies clearly indicate that the modified DNA is an effective inhibitor show‐
ing substantial difference in the recognition of CE-modified DNA over the native form [38].
The results also demonstrate the pro-oxidant condition which is generated due to the oxida‐
tive metabolism of estrogen [40, 36]. Non-enzymatic oxidation of CE in the presence of NO
[40] or Cu(II) [37] cause DNA modification and enhanced binding of these modified anti‐
gens to RA autoantibodies. To further confirm the role of CEs in RA, we evaluated the bind‐
ing of autoantibodies by quantitive precipitin titration. The apparent association constant
clearly indicates better recognition of CE-modified DNA over native by RA autoantibodies.
The enhanced recognition of CE-modified DNA by RA IgG indicates possible participation
of modified DNA in RA pathogenesis. The spontaneous production of autoantibodies in RA
might arise as a consequence of antigenic change in DNA. Therefore, it could be possible
that CE-modified bases of DNA might be one of the contributing factors towards the pro‐
duction of autoantibodies. However, the pro-inflammatory role of estrogen cannot be ruled
out [65]. It might be possible that estrogen caused T and B cell differentiation and increase
immunoglobulin production. These autoantibodies might be strongly bound with CE-modi‐
fied DNA than native polymer. Further more, DNA isolated from sera and SF of different
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RA patients caused appreciable inhibition in the activity of anti-CE-modified DNA antibod‐
ies clearly showing the presence of oxidatively altered epitopes on the isolated DNA mole‐
cules, which could be directly correlated to estrogen/radical mediated oxidative stress [38].
These studies show that hydroxylated estrogens (specially CEs) might have a role in the ae‐
tiopathogenesis of RA and other autoimmune diseases.
Various CE metabolites (4-OHE2, 4-OHE1, 2-OHE2, 2-OHE1) known to secret various cyto‐
kines from human peripheral blood leukocytes in presence of cortisol [32]. It has been dem‐
onstrated that the ratio of 16-hydroxylated estrogen in relation to 2-/4-hydroxylated
estrogen is important for TNF secretion. The study showed that the ratio of 10:1 of 16-OHE2
in relation to 2-/4-hydroxylated estrogens stimulate TNF secretion in the presence of cortisol
otherwise this effect was not observed in absence of this hormone. Furthermore, absence of
cortisol strongly inhibited TNF secretion if the combination of 16-OHE1 and 2-hydroxylated
estrogens were used in this experiment [32]. In addition, it has been demonstrated that es‐
trogens are able to enhance secretion of matrix metalloproteinase and IL-1β-induced IL-6 se‐
cretion from human fibroblast-like synoviocytes in RA [35]. However, with respect to serum
levels of estrogen in RA patients, they are not changed which is in strict contrast to andro‐
gen levels [13]. High estrogen concentration has been found in particular in SF of RA pa‐
tients. The presence in the RA SF of an altered sex hormone balance resulting in lower
immunosuppressive androgen and higher immunoenhancing estrogens might determine a
favourable condition for the development of the immune-mediated RA synovitis. The ap‐
propriated explanation for high concentration of estrogen (and their CE metabolites) can be
originated from the study that showed that the inflammatory cytokines (TNF-α, IL-1, IL-6)
are particularly increased in RA synovitis and stimulate aromatase activity in peripheral tis‐
sues [55]. Therefore, enzyme complex is responsible for the peripheral conversion of andro‐
gen to estrogen (estrone and estradiol). In addition, a significant correlation was found
between the aromatase activity and IL-6 production and aromatase has also been found sig‐
nificantly in synoviocytes [45]. Therefore, the increased aromatase activity induced by local‐
ly produced inflammatory cytokines (TNF-α, IL-1, IL-6) might explain the altered balance
resulting in lower androgens and higher estrogen in RA SF as well as their effects on synovi‐
al cells [15, 6]. In conclusion, an increase in 16-hydroxyestrogen relative to the sum of all 2-
and 4-hydroxylated estrogens (CE) must be viewed as a pro-inflammatory signal, which is
particularly evident in RA patients.
Elevated serum concentration of 16-OHE1 have been described in patients with SLE [43], in‐
dicating that abnormal pattern of estradiol metabolism may lead to increased estrogenic ac‐
tivity. Interestingly, similar phenomenon was observed in the synovial fluid of RA patients,
where 16-OHE1/4-OHE2 was found to be significantly higher compared with control fluid [6,
5]. 4-Hydroxylated estrogens were found to be mitogenic and thus have pro-inflammatory
effect [66, 68]. Importantly, all 2- and 4-hydroxylated estrogen demonstrated TNF-inhibitory
effect, which was not observed with 16 α-hydroxylated estrogen. Thus the observed prefer‐
ence of 16 α-hydroxylated over 2-/4-hydroxylated estrogens must be considered an impor‐
tant pro-inflammatory signal, which occur particularly in RA patients. This study also
describes methylation of hydroxylated estrogen metabolites (CEs) in addition to hydroxyla‐
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tion of estrone and estradiol. Catechol-o-methyl transferase, the only enzymes responsible
for the methylation of CEs, was also present in primary synovial cells, although it doesn’t
show any preference with either estrone or estradiol-hydroxylated substrate. Similar to the
2- and 4-hydroxylated forms of estrogen, the 2- and 4-methoxy form inhibited TNF secretion
from RA and osteoarthritis (OA) synovial cells [60]. These studies show that hydroxylated
estrogen (especially CEs) might have a role in the aetiopathogenesis of RA and other auto‐
immune diseases.
7. Conclusion
Remarkable progress have been made in understanding the role of estrogen in the etiology
of RA but the role of CEs in RA is lacking. Catechol metabolites known to play an important
role in RA but the exact patho-aetiology remain elusive. The evidence concerning the possi‐
bility of CEs in the development of RA is very limited and preliminary. It has been observed
that oxidative reactions, often catalyzed by isoforms of the cytochrome P-450, can result in
the formation of CEs from parent estrogen and subsequently, semiquinones and quinones
derived from CEs, are capable of forming either stable or depurinating DNA adducts. Oxi‐
dation of CEs also leads to high amount of ROS that can generate extensive DNA damage.
This would probably alter its immunogenicity leading to the induction and elevated levels
of RA autoantibodies (Figure 4). Therefore, it is possible that the CE-modified bases of DNA
might be one of the contributing factors towards production of SLE autoantibodies. In addi‐
tion, estrogen not only induces DNA damage but also modulate immune response and im‐
mune mediated disease. Estrogen was found to increase IgG and IgM from PBMC, which let
to elevated level of polyclonal IgG including IgG anti-ds DNA by enhancing B cell activity
via IL-10. These autoantibodies could be strongly bound to DNA and serve as an immuno‐
logical marker for the diagnosis of diseases. Estrogen is thought to play both pro- and anti-
inflammatory role in chronic inflammatory diseases that were found to be related to low
and high concentration. Increased estrogen to androgen ratio have been observed in RA pa‐
tients SF, perhaps due to increase aromatase expression by inflammatory macrophages infil‐
trating synovial tissues. The discovery of high concentration in SF from RA patients of both
sexes can also be explain by the fact that inflammatory cytokines (i.e. TNFα, IL-1, IL-6) are
increased in RA cynovitis and can markedly stimulate aromatase activity in peripheral tis‐
sue. But renal excretion studies showed that enhanced estrogen metabolism observed in RA
resulted in elevation of pro-inflammatory metabolites derived from estrone and estradiol
such as 16-OHE1 (or 4-OHE2, 4-OHE1) which exert mitogenic effect on different synovial fi‐
broblast. In contrast, RA SF have reduced amount of anti-inflammatory estrogen metabolites
such as 2-hydroxyestrogen that inhibit the growth-promoting effect of estradiol. An unwant‐
ed shift from 2- to 4-hydroxyestrogen might be an additional pro-inflammatory signal be‐
cause these 4-hydroxylated metabolites can be converted to 3,4-quinone, which lead to
depurination and mutation in DNA. In conclusion, an increase in 16-OHE1 relative to the
sum of all 2- and 4-hydroxylated estrogens must be considered as pro-inflammatory signal
which is particularly evident in RA [60].
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Figure 4. The proposed mechanism for the production autoantibodies in RA. 4-OHE2 (4-hydroxyestradiol), 2-OHE2 (2-
hydroxyestradiol), (E2)-3,4-SQ (Estradiol-3,4-semiquinone), (E2)-2,3-SQ (Estradiol-2,3-semiquinone), (E2)-3,4-Q (Estra‐
diol-3,4-quinone), (E2)-3,4-Q (Estradiol-2,3-quinone).
In light of these data, the review literature leads to the conclusion that CEs (and other me‐
tabolites) might have a role in the pathogenesis of RA. Based on the preliminary report, it
appears that the production of antibodies in RA involves the generation of IgG against CE-
modified DNA through oxidative induced DNA damage. Results imply that oxidative dam‐
age to DNA alter it immunogenicity leading to the induction and elevated levels of RA
antibodies. RA is a chronic, systemic, inflammatory condition that is characterized by in‐
creased production of inflammatory cytokines as well as alteration in estrogen metabolites
(CEs). Only by understanding the complex interaction between various estrogen metabolites
and mechanism of autoantibodies production, we will able to generate therapeutic interven‐
tions that can be designed to suppress synovial inflammation in RA.
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